查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1525326

全球碘缺乏药物市场规模研究，按剂型（片剂、其他）、配销通路（医院药房、药房和零售药房、线上提供者）以及 2022-2032 年区域预测

Global Iodine Deficiency Drug Market Size study, by Dosage Form (Tablets, Others), by Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers), and Regional Forecasts 2022-2032
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 285 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年全球缺碘药物市场价值约为41.4亿美元，预计在2024-2032年预测期内将以超过5.76%的健康成长率成长。碘缺乏症（IDD）是全球重大的公共卫生问题，原因是饮食中碘摄取不足，导致甲状腺激素产生不足。这种被称为甲状腺功能减退症的缺陷可能会影响所有年龄、性别和种族的人，但在各国 60 岁以上的女性和儿童中尤其普遍。製药公司正在积极致力于左旋甲状腺素药物的开发和批准，以满足不断增长的需求，特别是在医疗基础设施欠发达的地区。例如，2021年，Zydus Cadila宣布其治疗甲状腺功能低下的甲状腺药物已获得美国FDA批准。

全球甲状腺功能减退症盛行率的不断上升是推动市场对缺碘药物需求的关键驱动力。甲状腺功能减退症的特征是甲状腺激素分泌不足，通常是由于碘缺乏造成的，特别是在碘盐摄取不足的地区。随着人们越来越认识到碘对甲状腺功能的重要性，医疗保健提供者正在诊断更多的甲状腺功能减退症病例，从而增加了对碘补充疗法的需求。各国政府和卫生组织也正在实施解决碘缺乏问题的计划，进一步刺激市场成长。製药公司正在针对不同患者人口统计和地区需求推出创新的碘补充剂配方和剂型。这个驱动因素强调了碘缺乏药物在治疗甲状腺疾病中的关键作用，并强调了它们在全球公共卫生策略中日益重要的作用。然而，与左旋甲状腺素相关的副作用，例如不规则心悸，以及怀孕期间和心臟病患者定期血液检查的需要，限制了市场的成长。

全球缺碘药物市场的主要区域包括北美、欧洲、亚太地区、拉丁美洲、中东和非洲。 2023年，欧洲在收入方面主导全球缺碘药物市场，预计在2024-2032年预测期内成长最快。这是由于严格的公共卫生措施、广泛的碘盐计划以及对甲状腺疾病的高度认识。该地区各国优先考虑补充碘，以防止缺乏碘，导致甲状腺相关健康问题，如甲状腺功能减退和甲状腺肿。欧洲的製药公司专注于开发适合不同人群需求的有效碘补充剂。该地区在医疗基础设施和研究方面采取的积极主动的做法促进了持续创新，并确保了高标准的碘缺乏管理。这一领导地位巩固了欧洲在塑造全球碘缺乏药物市场的关键作用。

在全球碘缺乏药物市场中营运的主要公司包括

雅培实验室

艾伯维公司

西普拉有限公司

费森尤斯股份公司 (Fresenius Kabi)

葛兰素史克

羽扇豆

麦克劳兹製药公司

默克公司

辉瑞公司

梯瓦製药工业股份有限公司

目录

第 1 章：全球碘缺乏药物市场执行摘要

  • 全球碘缺乏药物市场规模及预测（2022-2032）
  • 区域概要
  • 分部摘要
    • 依剂型分类
    • 按配销通路
  • 主要趋势
  • 经济衰退的影响
  • 分析师推荐与结论

第 2 章：全球碘缺乏药物市场定义与研究假设

  • 研究目的
  • 市场定义
  • 研究假设
    • 包含与排除
    • 限制
    • 供给侧分析
      • 可用性
      • 基础设施
      • 监管环境
      • 市场竞争
      • 经济可行性（消费者的角度）
    • 需求面分析
      • 监理框架
      • 技术进步
      • 环境考虑
      • 消费者意识和接受度
  • 估算方法
  • 研究考虑的年份
  • 货币兑换率

第三章：全球碘缺乏药物市场动态

  • 市场驱动因素
    • 甲状腺功能低下症盛行率增加
    • 教育和意识计划
    • 儿童甲状腺功能低下症增加
  • 市场挑战
    • 左旋甲状腺素的副作用
    • 需要定期验血
  • 市场机会
    • 发展中地区的製药业兴趣
    • 研发投资

第 4 章：全球碘缺乏药物市场产业分析

  • 波特的五力模型
    • 供应商的议价能力
    • 买家的议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争竞争
    • 波特五力模型的未来方法
    • 波特的五力影响分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会的
    • 技术性
    • 环境的
    • 合法的
  • 顶级投资机会
  • 最佳制胜策略
  • 颠覆性趋势
  • 产业专家视角
  • 分析师推荐与结论

第 5 章：全球碘缺乏药物市场规模与预测：按剂型 - 2022-2032

  • 细分仪表板
  • 全球缺碘药物市场：剂型收入趋势分析，2022 年和 2032 年
    • 平板电脑
    • 其他的

第 6 章：全球碘缺乏药物市场规模与预测：按配销通路- 2022-2032

  • 细分仪表板
  • 全球缺碘药物市场：2022 年和 2032 年配销通路收入趋势分析
    • 医院药房
    • 药局和零售药局
    • 线上提供者

第 7 章：全球碘缺乏药物市场规模及预测：按地区 - 2022-2032

  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 中东和非洲其他地区

第 8 章：竞争情报

  • 重点企业SWOT分析
  • 顶级市场策略
  • 公司简介
    • Abbott Laboratories
      • 关键讯息
      • 概述
      • 财务（视数据可用性而定）
      • 产品概要
      • 市场策略
    • AbbVie Inc.
    • Cipla Ltd.
    • Fresenius SE & Co. KGaA (Fresenius Kabi)
    • GlaxoSmithKline
    • Lupin
    • Macleods Pharmaceuticals
    • Merck KGaA
    • Pfizer
    • Teva Pharmaceutical Industries Ltd., Inc.

第 9 章：研究过程

  • 研究过程
    • 资料探勘
    • 分析
    • 市场预测
    • 验证
    • 出版
  • 研究属性
简介目录

The Global Iodine Deficiency Drug Market is valued approximately at USD 4.14 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.76% over the forecast period 2024-2032. Iodine Deficiency Disorders (IDD) represent a significant public health issue globally, resulting from inadequate dietary intake of iodine, which leads to insufficient thyroid hormone production. This deficiency, known as hypothyroidism, can affect individuals of all ages, genders, and ethnicities, though it is particularly prevalent among women over the age of 60 and children in various countries. Pharmaceutical companies are actively focusing on the development and approval of levothyroxine drugs to meet the increasing demand, particularly in regions with underdeveloped healthcare infrastructure. For instance, in 2021, Zydus Cadila announced that it has received U.S. FDA approval for its thyroid drug for hypothyroidism.

The increasing prevalence of hypothyroidism globally is a key driver propelling the demand for iodine deficiency drugs in the market. Hypothyroidism, characterized by insufficient thyroid hormone production, often results from iodine deficiency, especially in regions where iodized salt intake is inadequate. As awareness grows about the importance of iodine in thyroid function, healthcare providers are diagnosing more cases of hypothyroidism, thereby boosting the need for iodine supplementation therapies. Governments and health organizations are also implementing programs to address iodine deficiency, further stimulating market growth. Pharmaceutical companies are responding with innovative formulations and dosage forms of iodine supplements tailored to different patient demographics and regional needs. This driver underscores the critical role of iodine deficiency drugs in managing thyroid disorders and highlights their increasing importance in public health strategies worldwide. However, side effects associated with levothyroxine, such as irregular heart palpitations, and the need for regular blood tests during pregnancy and in heart patients restrain market growth.

The key region in the Global Iodine Deficiency Drugs Market includes North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2023, the Europe dominates the Global Iodine Deficiency Drugs Market in terms of revenue and expected to grow fastest during the forecast period 2024-2032. This is due to stringent public health measures, widespread iodized salt programs, and high awareness of thyroid disorders. Countries across the region prioritize iodine supplementation to prevent deficiencies, which contribute to thyroid-related health issues like hypothyroidism and goiter. Pharmaceutical companies in Europe focus on developing effective iodine supplements tailored to diverse population needs. The region's proactive approach in healthcare infrastructure and research fosters continuous innovation and ensures high standards of iodine deficiency management. This leadership solidifies Europe's pivotal role in shaping the global market for iodine deficiency drugs.

Major companies operating in the Global Iodine Deficiency Drug Market include

Abbott Laboratories

AbbVie Inc.

Cipla Ltd.

Fresenius SE & Co. KGaA (Fresenius Kabi)

GlaxoSmithKline

Lupin

Macleods Pharmaceuticals

Merck KGaA

Pfizer

Teva Pharmaceutical Industries Ltd., Inc.

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • RoMEA

Years considered for the study are as follows:

  • Historical year - 2022
  • Base year - 2023
  • Forecast period - 2024 to 2032

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Iodine Deficiency Drug Market Executive Summary

  • 1.1. Global Iodine Deficiency Drug Market Size & Forecast (2022-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Dosage Form
    • 1.3.2. By Distribution Channel
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Iodine Deficiency Drug Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Consumer's Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Consumer Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global Iodine Deficiency Drug Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Increase in Prevalence of Hypothyroidism
    • 3.1.2. Education and Awareness Programs
    • 3.1.3. Increase in Hypothyroidism in Children
  • 3.2. Market Challenges
    • 3.2.1. Side Effects of Levothyroxine
    • 3.2.2. Need for Regular Blood Tests
  • 3.3. Market Opportunities
    • 3.3.1. Pharmaceutical Interest in Developing Regions
    • 3.3.2. R&D Investments

Chapter 4. Global Iodine Deficiency Drug Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model
    • 4.1.7. Porter's 5 Force Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top Investment Opportunity
  • 4.4. Top Winning Strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Iodine Deficiency Drug Market Size & Forecasts by Dosage Form 2022-2032

  • 5.1. Segment Dashboard
  • 5.2. Global Iodine Deficiency Drug Market: Dosage Form Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 5.2.1. Tablets
    • 5.2.2. Others

Chapter 6. Global Iodine Deficiency Drug Market Size & Forecasts by Distribution Channel 2022-2032

  • 6.1. Segment Dashboard
  • 6.2. Global Iodine Deficiency Drug Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 6.2.1. Hospital Pharmacies
    • 6.2.2. Drug Stores and Retail Pharmacies
    • 6.2.3. Online Providers

Chapter 7. Global Iodine Deficiency Drug Market Size & Forecasts by Region 2022-2032

  • 7.1. North America Iodine Deficiency Drug Market
    • 7.1.1. U.S. Iodine Deficiency Drug Market
      • 7.1.1.1. Dosage Form breakdown size & forecasts, 2022-2032
      • 7.1.1.2. Distribution Channel breakdown size & forecasts, 2022-2032
    • 7.1.2. Canada Iodine Deficiency Drug Market
  • 7.2. Europe Iodine Deficiency Drug Market
    • 7.2.1. U.K. Iodine Deficiency Drug Market
    • 7.2.2. Germany Iodine Deficiency Drug Market
    • 7.2.3. France Iodine Deficiency Drug Market
    • 7.2.4. Spain Iodine Deficiency Drug Market
    • 7.2.5. Italy Iodine Deficiency Drug Market
    • 7.2.6. Rest of Europe Iodine Deficiency Drug Market
  • 7.3. Asia-Pacific Iodine Deficiency Drug Market
    • 7.3.1. China Iodine Deficiency Drug Market
    • 7.3.2. India Iodine Deficiency Drug Market
    • 7.3.3. Japan Iodine Deficiency Drug Market
    • 7.3.4. Australia Iodine Deficiency Drug Market
    • 7.3.5. South Korea Iodine Deficiency Drug Market
    • 7.3.6. Rest of Asia Pacific Iodine Deficiency Drug Market
  • 7.4. Latin America Iodine Deficiency Drug Market
    • 7.4.1. Brazil Iodine Deficiency Drug Market
    • 7.4.2. Mexico Iodine Deficiency Drug Market
    • 7.4.3. Rest of Latin America Iodine Deficiency Drug Market
  • 7.5. Middle East & Africa Iodine Deficiency Drug Market
    • 7.5.1. Saudi Arabia Iodine Deficiency Drug Market
    • 7.5.2. South Africa Iodine Deficiency Drug Market
    • 7.5.3. Rest of Middle East & Africa Iodine Deficiency Drug Market

Chapter 8. Competitive Intelligence

  • 8.1. Key Company SWOT Analysis
  • 8.2. Top Market Strategies
  • 8.3. Company Profiles
    • 8.3.1. Abbott Laboratories
      • 8.3.1.1. Key Information
      • 8.3.1.2. Overview
      • 8.3.1.3. Financial (Subject to Data Availability)
      • 8.3.1.4. Product Summary
      • 8.3.1.5. Market Strategies
    • 8.3.2. AbbVie Inc.
    • 8.3.3. Cipla Ltd.
    • 8.3.4. Fresenius SE & Co. KGaA (Fresenius Kabi)
    • 8.3.5. GlaxoSmithKline
    • 8.3.6. Lupin
    • 8.3.7. Macleods Pharmaceuticals
    • 8.3.8. Merck KGaA
    • 8.3.9. Pfizer
    • 8.3.10. Teva Pharmaceutical Industries Ltd., Inc.

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes